F.H. van Wijk

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Matti Aapro, F.H. van Wijk, Giorgio Bolis et al. · Annals of Oncology · 2003 · 200 citations · Full text

Doxorubicin Versus Doxorubicin, Medicine, Gynecology +9

Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group

F.H. van Wijk, C. Lhommé, Giorgio Bolis et al. · European Journal of Cancer · 2002 · 40 citations

Tumoral Pathology, Medicine, Gynecology +8

Molecular Portrait of the Progestagenic and Estrogenic Actions of Tibolone: Behavior of Cellular Networks in Response to Tibolone

Payman Hanifi‐Moghaddam, S. C. J. P. Gielen, H.J. Kloosterboer et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 25 citations · Full text

Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen + progestagen signaling

Payman Hanifi‐Moghaddam, B. Boers-Sijmons, Anet H.A. Klaassens et al. · Journal of Molecular Medicine · 2007 · 21 citations · Full text

Histological and immunohistochemical evaluation of postmenopausal endometrium after 3 weeks of treatment with tibolone, estrogen only, or estrogen plus progestagen

Anet H.A. Klaassens, F.H. van Wijk, Payman Hanifi‐Moghaddam et al. · Fertility and Sterility · 2006 · 18 citations · Full text